Genetic testing can pinpoint the cause of sudden unexplained cardiac death, but postmortem testing options are limited. In this test-specific episode of the "Answers From the Lab" podcast, Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' unique testing suite can provide answers and guide care for surviving family members.

Genetic testing typically requires whole blood samples, which often aren't collected postmortem. Mayo Clinic Laboratories' new tests (Test IDs: PMAOG, PMARG, PMCAG, PMCMG, PMHLH, and PCMSP) use formalin-fixed paraffin-embedded, or FFPE, tissue to identify disease-causing genetic variants.

"FFPE tissue may be the only specimen available for genetic testing for patients who may have died suddenly due to a cardiac event. And we are currently one of the only labs worldwide that offers genetic testing on post-mortem FFPE specimens," Kotzer says.

Underlying heart conditions are the most common cause of sudden unexplained death and are especially frequent in younger people.

"We are able to test specimens from individuals who passed away years ago and whose families are still searching for answers," Dr. Baudhuin says. "Identifying genetic variants is a huge benefit that helps to tailor family members' testing and medical management."

Listen to learn more about Mayo Clinic Laboratories' Postmortem Cardiovascular Genetic Testing.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PMAOG   | Postmortem Aortopathy Gene Panel, Tissue

PMARG   | Postmortem Arrhythmia Gene Panel, Tissue

PMCAG   | Postmortem Cardiomyopathy and Arrhythmia Gene Panel, Tissue

PMCMG   | Postmortem Cardiomyopathy Gene Panel, Tissue

PMHLH   | Postmortem Primary Hemophagocytic Lymphohistiocytosis (HLH) Gene Panel, Tissue

PCMSP   | Postmortem Inherited Congenital Myasthenia Syndrome Gene Panel, Tissue

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less